|

nab-Sirolimus Clinical Trials

5 actively recruiting trials across 5 locations

▼ -1 trial since June 2026

Also known as: ABI-009, ABI-009, nab-rapamycin, albumin-bound rapamycin, Fyarro

Pipeline

Phase 1: 2Phase 2: 3

Top Sponsors

  • Aadi Bioscience, Inc.3
  • Sarcoma Alliance for Research through Collaboration1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer5
  • Tumor2
  • Pulmonary Neuroendocrine Tumor1
  • Endometrioid Endometrial Cancer1
  • Endometrioid Tumor1

Little Rock, Arkansas1 trial

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Michael Birrer, MD, PhD

Phase 2

Newport Beach, California1 trial

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Hoag Memorial Hospital Presbyterian

Phase 2

Stanford, California1 trial

SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

Stanford University

Phase 2

Houston, Texas1 trial

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

MD Anderson Cancer Center

Phase 1

San Antonio, Texas1 trial

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

South Texas Accelerated Research Therapeutics, LLC

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.